Pfizer Says Metsera Drug Produced 12.3% Weight Loss in Study

Pfizer Inc. said that a monthly regimen of an obesity drug obtained in its deal for Metsera Inc. produced up to 12.3% weight loss after 28 weeks compared to a placebo.

The results from the mid-stage study shows that less frequent dosing of the GLP-1 medicine may be possible. In a previous trial announced by Metsera in September, the drug led to weight loss of as much as 14.1% compared to a placebo when used at weekly dosing.